On-Site Magazine

Phase 1 of OmniaBio CDMO project delivered

By Adam Freill   

Commercial Construction Industrial

Multiplex Construction Canada completes work on cell and gene therapy manufacturing facility at McMaster Innovation Park in Hamilton, Ont.

Representatives from Multiplex Construction Canada and McMaster Innovation Park (l-r) Brian Farrelly, Scott Rasmussen, Atiaan Stander, Sandra Tran, Frances Grabowski, Ty J. Shattuck, Terry Olynyk and Pedro Duarte stopped for a quick photo-op during a tour of the OmniaBio facility. (CNW Group/McMaster Innovation Park)

One year after initiating construction on the OmniaBio B Building at McMaster Innovation Park (MIP), Multiplex Construction Canada has delivered the OmniaBio B Base Build. Executed under an Integrated Project Delivery (IPD) method, Multiplex provided the core and shell infrastructure for accessibility to MIP and its partners, OmniaBio on-time and on-budget.

Frances Grabowski, vice-president of development and design at MIP, and the lead of the IPD team, expressed her satisfaction with the project’s conclusion. The facility will provide space for a Contract Development and Manufacturing Organization (CDMO), a structure used in the pharmaceutical sector for drug development and manufacturing.

“The OmniaBio project exemplifies the efficacy of integrated project delivery,” stated Grabowski. “Our vision was to streamline the construction process and expedite the development of a cutting-edge CDMO infrastructure. Through effective collaboration and an unwavering commitment to excellence, we successfully realized our objectives.”

Multiplex Construction Canada president and managing director, Terry Olynyk, also shared that he takes “immense pride in the dedication and hard work demonstrated by our entire construction team.”


He said that his team’s tireless efforts and steadfast commitment to delivering projects of the highest quality were instrumental in the project’s success.

“The collaboration fostered through the integrated project delivery approach has been instrumental in our success,” he said. “We are delighted to celebrate this significant milestone alongside MIP, trade partners, consultants, and the broader community.”

OmniaBio, planned at 400,000 square feet, will be the largest CDMO exclusively manufacturing for cell and gene therapies in Canada. MIP has now delivered the core and shell of the first, 90,000-square-foot phase. The building’s occupancy is expected to take place this summer.




Stories continue below